Skip to main content

LabCorp Buy of Genzyme Genetics Clears FTC

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said that its $925 million proposed acquisition of Genzyme Genetics has cleared antitrust review.

The Burlington, N.C.-based medical laboratory testing and services firm said that it has received early termination from the Federal Trade Commission of the waiting period under the federal Hart-Scott-Rodino Antitrust Improvement Act of 1976, clearing one hurdle for LabCorp to close the purchase of Genzyme Genetics on or around Dec. 1.

The deal is expected to have a net cash cost to LabCorp of about $795 million, after income tax benefits and acquisition-related costs have been factored in.

Genyzme Genetics, a business unit of Genzyme, performs more than 1.5 million clinical tests each year. In 2009, it generated about $371 million in revenues. The menu of services it provides includes maternal serum screening, prenatal diagnostics, carrier screening, and postnatal testing.

The sale of the business is part of a strategy by Genzyme to concentrate on its core business.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.